endofocusFOCUS ЭндокринологияFOCUS. Endocrinology2713-01772713-0185ООО "Издательство "Перо"10.62751/2713-0177-2026-7-1-04endofocus-174Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWSЭугликемический диабетический кетоацидоз: современные представления о патогенезе, диагностике и леченииEuglycemic diabetic ketoacidosis: Current understanding of pathogenesis, diagnosis, and treatmenthttps://orcid.org/0000-0003-4705-3823БыковЮ. В.BykovYu. V.

Юрий Витальевич Быков, к. м. н., доцент

кафедра анестезиологии и реаниматологии с курсом ДПО

355017; ул. Мира, д. 310; Ставрополь

Yuri V. Bykov, Cand. Sci. (Med.), Associate Professor

Department of Anesthesiology and Intensive Care with a additional professional education course

355017; 310, Mira str.; Stavropol

yubukov@gmail.comСтавропольский государственный медицинский университетStavropol State Medical University202603052026713138Copyright © Быков Ю.В., 20262026Быков Ю.В.Bykov Y.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://endofocus.elpub.ru/jour/article/view/174

   Эугликемический диабетический кетоацидоз (ЭДКА) представляет собой особую форму диабетического кетоацидоза, характеризующуюся выраженным метаболическим ацидозом при нормогликемии. Рост частоты ЭДКА связан с широким применением ингибиторов натрий-глюкозного котранспортера 2 типа. В обзоре обобщены современные данные о патогенезе, факторах риска, диагностических критериях и принципах терапии ЭДКА. Подчеркнута необходимость раннего распознавания и своевременной коррекции нарушений водно-электролитного баланса для предупреждения осложнений.

   Особое внимание уделено клиническим особенностям течения ЭДКА у пациентов, получающих ингибиторы натрий-глюкозного котранспортера 2 типа, и вопросам профилактики рецидивов.

   Систематизация имеющихся знаний позволяет повысить настороженность врачей и оптимизировать ведение пациентов с этим осложнением сахарного диабета.

   Euglycemic diabetic ketoacidosis (EDKA) is a distinct form of diabetic ketoacidosis characterized by severe metabolic acidosis in the presence of normal blood glucose levels. The increasing incidence of EDKA is associated with the widespread use of sodium-glucose cotransporter type 2 (SGLT2) inhibitors. This review summarizes current data on the pathogenesis, risk factors, diagnostic criteria, and therapeutic approaches to EDKA. Emphasis is placed on the importance of early recognition and timely correction of water–electrolyte imbalance to prevent complications.

   Special attention is given to the clinical features of EDKA in patients receiving SGLT2 inhibitors and to strategies for preventing recurrence.

   Systematization of existing knowledge may improve clinicians’ awareness and optimize the management of patients with this potentially life-threatening complication of diabetes mellitus.

эугликемический диабетический кетоацидозсахарный диабетингибиторы натрий-глюкозного котранспортера 2 типаметаболический ацидозкетонемияинсулинотерапияэлектролитные нарушенияeuglycemic diabetic ketoacidosisdiabetes mellitussodium-glucose cotransporter type 2 inhibitorsmetabolic acidosisketonemiainsulin therapyelectrolyte disturbancesОтсутствуетNoneReferencesДедов И.И., Шестакова М.В., Викулова О.К., Железнякова А.В., Исаков М.А., Кутакова Д.В., Мокрышева Н.Г. Эпидемиология и ключевые клинико-терапевтические показатели сахарного диабета в Российской Федерации в разрезе стратегических целей Всемирной организации здравоохранения. Сахарный диабет. 2025;28(1):4–17. doi: 10.14341/DM13292Dedov II, Shestakova MV, Vikulova OK, Zheleznyakova AV, Isakov MA, Kutakova DV, Mokrysheva NG. Epidemiology and key clinical and therapeutic indicators of diabetes mellitus in the Russian Federation in the context of the strategic goals of the World Health Organization. Sakharnyi diabet = Diabetes Mellitus. 2025;28(1):4–17 (In Russ.) doi: 10.14341/DM13292Dagdeviren M, Akkan T, Ertugrul DT. Re-emergence of a forgotten diabetes complication: Euglycemic diabetic ketoacidosis. Turk J Emerg Med. 2024;24(1):1–7. doi: 10.4103/tjem.tjem_110_23Dagdeviren M, Akkan T, Ertugrul DT. Re-emergence of a forgotten diabetes complication: Euglycemic diabetic ketoacidosis. Turk J Emerg Med. 2024;24(1):1–7. doi: 10.4103/tjem.tjem_110_23Ветрова А.В., Хворостенко Н.В. Клинический случай эугликеического диабетического кетоацидоза на фоне длительного и бесконтрольного приема iSGLT2. Молодой ученый. 2024;(52):168–171.Vetrova AV, Khvorostenko NV. A clinical case of euglycemic diabetic ketoacidosis associated with prolonged and uncontrolled use of iSGLT2 inhibitors. Molodoy uchenyy = Young Scientist. 2024;(52):168–171 (In Russ.)Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al.; IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract. 2019;157:107843. doi: 10.1016/j.diabres.2019.107843Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al.; IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract. 2019;157:107843. doi: 10.1016/j.diabres.2019.107843Быков Ю.В. Диабетический кетоацидоз у детей и подростков: от патофизиологии до профилактики. Забайкальский медицинский вестник. 2021;(2):85–95. doi: 10.52485/19986173_2021_2_85Bykov YuV. Diabetic ketoacidosis in children and adolescents: From pathophysiology to prevention. Zabaykalskiy meditsinskiy vestnik = Transbaikal Medical Bulletin. 2021;(2):85–95 (In Russ.) doi: 10.52485/19986173_2021_2_85Быков Ю.В. К вопросу о патофизиологии диабетического кетоацидоза: классические механизмы и новые гипотезы. Современные проблемы науки и образования. 2023;(5):105. doi: 10.17513/spno.33009Bykov YuV. On the pathophysiology of diabetic ketoacidosis: classical mechanisms and new hypotheses. Sovremennye problemy nauki i obrazovaniya = Modern Problems of Science and Education. 2023;(5):105 (In Russ.) doi: 10.17513/spno.33009Cardona Z, Friedman JG, Kamal N, Oakes DJ, Wallia A, Aleppo G, et al. Developing a protocol for management of euglycemic diabetic ketoacidosis. Curr Diab Rep. 2025;25(1):48. doi: 10.1007/s11892-025-01604-3Cardona Z, Friedman JG, Kamal N, Oakes DJ, Wallia A, Aleppo G, et al. Developing a protocol for management of euglycemic diabetic ketoacidosis. Curr Diab Rep. 2025;25(1):48. doi: 10.1007/s11892-025-01604-3Plewa MC, Bryant M, King-Thiele R. Euglycemic diabetic ketoacidosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.Plewa MC, Bryant M, King-Thiele R. Euglycemic diabetic ketoacidosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.Nasa P, Chaudhary S, Shrivastava PK, Singh A. Euglycemic diabetic ketoacidosis: A missed diagnosis. World J Diabetes. 2021;12(5):514–23. doi: 10.4239/wjd.v12.i5.514Nasa P, Chaudhary S, Shrivastava PK, Singh A. Euglycemic diabetic ketoacidosis: A missed diagnosis. World J Diabetes. 2021;12(5):514–23. doi: 10.4239/wjd.v12.i5.514Салухов В.В., Галстян Г.Р., Ильинская Т.С. Практические аспекты инициации и применения ингибиторов SGLT2 в стационаре и на амбулаторном этапе. Сахарный диабет. 2022;25(3):275–287. doi: 10.14341/DM12855Salukhov VV, Galstyan GR, Ilyinskaya TS. Practical aspects of initiation and use of SGLT2 inhibitors in inpatient and outpatient settings. Sakharnyy diabet = Diabetes Mellitus. 2022;25(3):275–287 (In Russ.) doi: 10.14341/DM12855Магрупов А.Х., Абдухалилов Н.Р., Алиева Б.Б., Жумабиев Р.Е., Онгарбаев Б.Т. Эугликемический диабетический кетоацидоз на фоне терапии ингибиторами SGLT2-рецепторов у пациентов онкохирургического профиля в раннем послеоперационном периоде: клинический случай. Онкология и радиология Казахстана. 2025;(1):90–94. doi: 10.52532/2521-6414-2025-1-75-424Magrupov AKh, Abdukhalilov NR, Alieva BB, Zhumabiev RE, Ongarbaev BT. Euglycemic diabetic ketoacidosis associated with SGLT2 receptor inhibitor therapy in oncological surgical patients in the early postoperative period: A clinical case. Onkologiya i radiologiya Kazakhstana = Oncology and Radiology of Kazakhstan. 2025;(1):90–94 (In Russ.) doi: 10.52532/2521-6414-2025-1-75-424Стронгин Л.Г., Малышева Е.С., Сергеева Т.В., Тизяева С.А., Морозова Е.П. Случай эугликемического диабетического кетоацидоза, ассоциированного с применением ингибиторов натрий-глюкозного котранспортера 2-го типа. Focus Эндокринология. 2020;(1):60–65. doi: 10.47407/ef2020.1.1.0008Strongin LG, Malysheva ES, Sergeeva TV, Tizyaeva SA, Morozova EP. A case of euglycemic diabetic ketoacidosis associated with the use of sodium-glucose cotransporter type 2 inhibitors. Focus Endokrinologia = Focus Endocrinology. 2020;(1):60–65 (In Russ.) doi: 10.47407/ef2020.1.1.0008Yu X, Zhang S, Zhang L. Newer perspectives of mechanisms for euglycemic diabetic ketoacidosis. Int J Endocrinol. 2018;2018:7074868. doi: 10.1155/2018/7074868Yu X, Zhang S, Zhang L. Newer perspectives of mechanisms for euglycemic diabetic ketoacidosis. Int J Endocrinol. 2018;2018:7074868. doi: 10.1155/2018/7074868Secinaro E, Ciavarella S, Rizzo G, Porreca E, Vitacolonna E. SGLT2-inhibitors and euglycemic diabetic ketoacidosis in COVID-19 pandemic era: A case report. Acta Diabetol. 2022;59(10):1391–94. doi: 10.1007/s00592-022-01909-9Secinaro E, Ciavarella S, Rizzo G, Porreca E, Vitacolonna E. SGLT2-inhibitors and euglycemic diabetic ketoacidosis in COVID-19 pandemic era: A case report. Acta Diabetol. 2022;59(10):1391–94. doi: 10.1007/s00592-022-01909-9Катушкина Ю.А., Татаринцева З.Г., Космачева Е.Д. Случай тяжелого эугликемического кетоацидоза на фоне приема дапаглифлозина. Терапия. 2024;10(6):129–36. doi: 10.18565/therapy.2024.6.129-136Katushkina YuA, Tatarintseva ZG, Kosmacheva ED. A case of severe euglycemic ketoacidosis arising during dapagliflozin intake. Therapy = Terapiya. 2024;10(6):129–36 (In Russ.) doi: 10.18565/therapy.2024.6.129-136Mehta AE, Zimmerman R. Classic diabetic ketoacidosis and the euglycemic variant: Something old, something new. Cleve Clin J Med. 2025;92(1):33–39. doi: 10.3949/ccjm.92a.24075Mehta AE, Zimmerman R. Classic diabetic ketoacidosis and the euglycemic variant: Something old, something new. Cleve Clin J Med. 2025;92(1):33–39. doi: 10.3949/ccjm.92a.24075Somagutta MR, Agadi K, Hange N, Jain MS, Batti E, Emuze BO, et al. Euglycemic diabetic ketoacidosis and sodium-glucose cotransporter-2 inhibitors : A focused review of pathophysiology, risk factors, and triggers. Cureus. 2021;13(3):e13665. doi: 10.7759/cureus.13665Somagutta MR, Agadi K, Hange N, Jain MS, Batti E, Emuze BO, et al. Euglycemic diabetic ketoacidosis and sodium-glucose cotransporter-2 inhibitors : A focused review of pathophysiology, risk factors, and triggers. Cureus. 2021;13(3):e13665. doi: 10.7759/cureus.13665Rosenstock J, Marquard J, Laffel LM, Neubacher D, Kaspers S, Cherney DZ, et al. Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: The EASE trials. Diabetes Care. 2018;41(12):2560–69. doi: 10.2337/dc18-1749Rosenstock J, Marquard J, Laffel LM, Neubacher D, Kaspers S, Cherney DZ, et al. Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: The EASE trials. Diabetes Care. 2018;41(12):2560–69. doi: 10.2337/dc18-1749Liu J, Li L, Li S, Wang Y, Qin X, Deng K, et al. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes : A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2020;22(9):1619–27. doi: 10.1111/dom.14075Liu J, Li L, Li S, Wang Y, Qin X, Deng K, et al. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes : A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2020;22(9):1619–27. doi: 10.1111/dom.14075Diabetes Care in the hospital: Standards of care in diabetes-2025. Diabetes Care. 2025;48(Supplement_1):S321–34. doi: 10.2337/dc25-S016Diabetes Care in the hospital: Standards of care in diabetes-2025. Diabetes Care. 2025;48(Supplement_1):S321–34. doi: 10.2337/dc25-S016Eshkoli T, Barski L, Faingelernt Y, Jotkowitz A, Finkel-Oron A, Schwarzfuchs D. Diabetic ketoacidosis in pregnancy : Case series, pathophysiology, and review of the literature. Eur J Obstet Gynecol Reprod Biol. 2022;269:41–46. doi: 10.1016/j.ejogrb.2021.12.011Eshkoli T, Barski L, Faingelernt Y, Jotkowitz A, Finkel-Oron A, Schwarzfuchs D. Diabetic ketoacidosis in pregnancy : Case series, pathophysiology, and review of the literature. Eur J Obstet Gynecol Reprod Biol. 2022;269:41–46. doi: 10.1016/j.ejogrb.2021.12.011Barski L, Eshkoli T, Brandstaetter E, Jotkowitz A. Euglycemic diabetic ketoacidosis. Eur J Intern Med. 2019;63:9–14. doi: 10.1016/j.ejim.2019.03.014Barski L, Eshkoli T, Brandstaetter E, Jotkowitz A. Euglycemic diabetic ketoacidosis. Eur J Intern Med. 2019;63:9–14. doi: 10.1016/j.ejim.2019.03.014Koceva A, Kravos Tramsek NA. From sweet to sour: SGLT-2-inhibitor-induced euglycemic diabetic ketoacidosis. J Pers Med. 2024;14(7):665. doi: 10.3390/jpm14070665Koceva A, Kravos Tramsek NA. From sweet to sour: SGLT-2-inhibitor-induced euglycemic diabetic ketoacidosis. J Pers Med. 2024;14(7):665. doi: 10.3390/jpm14070665Chow E, Clement S, Garg R. Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors. BMJ Open Diabetes Res Care. 2023;11(5):e003666. doi: 10.1136/bmjdrc-2023-003666Chow E, Clement S, Garg R. Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors. BMJ Open Diabetes Res Care. 2023;11(5):e003666. doi: 10.1136/bmjdrc-2023-003666Long B, Lentz S, Koyfman A, Gottlieb M. Euglycemic diabetic ketoacidosis: Etiologies, evaluation, and management. Am J Emerg Med. 2021;44:157–60. doi: 10.1016/j.ajem.2021.02.015Long B, Lentz S, Koyfman A, Gottlieb M. Euglycemic diabetic ketoacidosis: Etiologies, evaluation, and management. Am J Emerg Med. 2021;44:157–60. doi: 10.1016/j.ajem.2021.02.015Zughaib MT, Patel K, Leka M, Affas S. Self-induced euglycemic diabetic ketoacidosis: When to stop the drip. Cureus. 2022;14(1):e21768. doi: 10.7759/cureus.21768Zughaib MT, Patel K, Leka M, Affas S. Self-induced euglycemic diabetic ketoacidosis: When to stop the drip. Cureus. 2022;14(1):e21768. doi: 10.7759/cureus.21768Wan Azman SS, Sukor N, Abu Shamsi MY, Ismail I, Kamaruddin NA. Case report: High-calorie glucose infusion and tight glycemic control in ameliorating refractory acidosis of empagliflozin-induced euglycemic diabetic ketoacidosis. Front Endocrinol (Lausanne). 2022;13:867647. doi: 10.3389/fendo.2022.867647Wan Azman SS, Sukor N, Abu Shamsi MY, Ismail I, Kamaruddin NA. Case report: High-calorie glucose infusion and tight glycemic control in ameliorating refractory acidosis of empagliflozin-induced euglycemic diabetic ketoacidosis. Front Endocrinol (Lausanne). 2022;13:867647. doi: 10.3389/fendo.2022.867647Dhatariya KK, Glaser NS, Codner E, Umpierrez GE. Diabetic ketoacidosis. Nat Rev Dis Primers. 2020;6(1):40. doi: 10.1038/s41572-020-0165-1Dhatariya KK, Glaser NS, Codner E, Umpierrez GE. Diabetic ketoacidosis. Nat Rev Dis Primers. 2020;6(1):40. doi: 10.1038/s41572-020-0165-1Bonora BM, Avogaro A, Fadini GP. Euglycemic ketoacidosis. Curr Diab Rep. 2020;20(7):25. doi: 10.1007/s11892-020-01307-xBonora BM, Avogaro A, Fadini GP. Euglycemic ketoacidosis. Curr Diab Rep. 2020;20(7):25. doi: 10.1007/s11892-020-01307-xSampani E, Sarafidis P, Dimitriadis C, Kasimatis E, Daikidou D, Bantis K, et al. Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin : Case report and literature review. BMC Nephrol. 2020;21(1):276. doi: 10.1186/s12882-020-01930-6.Sampani E, Sarafidis P, Dimitriadis C, Kasimatis E, Daikidou D, Bantis K, et al. Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin : Case report and literature review. BMC Nephrol. 2020;21(1):276. doi: 10.1186/s12882-020-01930-6.

The authors declare that there are no conflicts of interest present.